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Antigen presenting cells from the cervical mucosa are thought to amplify incoming HIV-1
and spread infection systemically without being productively infected. Yet, the molecular
mechanism at the cervical mucosa underlying this viral transmission pathway remains
unknown. Here we identified a subset of HLA-DR+ CD14+ CD11c+ cervical DCs at the
lamina propria of the ectocervix and the endocervix that expressed the type-I interferon
inducible lectin Siglec-1 (CD169), which promoted viral uptake. In the cervical biopsy
of a viremic HIV-1+ patient, Siglec-1+ cells harbored HIV-1-containing compartments,
demonstrating that in vivo, these cells trap viruses. Ex vivo, a type-I interferon antiviral
environment enhanced viral capture and trans-infection via Siglec-1. Nonetheless, HIV-1
transfer via cervical DCs was effectively prevented with antibodies against Siglec-1.
Our findings contribute to decipher how cervical DCs may boost HIV-1 replication and
promote systemic viral spread from the cervical mucosa, and highlight the importance of
including inhibitors against Siglec-1 in microbicidal strategies.
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INTRODUCTION
Women account for 51% of people living with HIV worldwide, and in 2017 this represented
18.8 million of females (1). Since HIV-1 infection is mostly acquired by sexual transmission
(2), understanding the female genital tract immunobiology is imperative not only to halt novel
infections, but also to design strategies that will limit HIV-1 spread within the mucosa and contain
the virus during the early stages of infection. HIV-1 acquisition requires a series of orchestrated
events that lead to systemic infection, beginning with viral entry through the genital epithelium
and followed by the productive infection of distinct CD4+ target cells that reside within the
mucosa. Local infection is early disseminated to draining lymph nodes, aiding to spread HIV-1
systemically and boost viral replication (3). While current antiviral agents are potent inhibitors of
viral infection in the mucosa, efficacy of preventive methods is also critically dependent on effective
blockade of all potential receptors involved in HIV-1 dissemination from the genital mucosa to
the lymphoid tissues (4–6). Yet, the precise molecular mechanisms underlying viral dissemination
routes from the genital mucosa that boost systemic HIV-1 infection remain unknown.
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Although productive infection during the first days after
vaginal SIV exposure is low and mainly restricted to the
cervicovaginal tissues (3), evidence for rapid dissemination to
the draining lymph nodes has been demonstrated as soon as
24 h post-infection (7–9). These studies suggest a critical role
for cervical myeloid cells and, particularly, dendritic cells (DCs)
in the early dissemination of mucosal viruses to lymphoid
tissues. Importantly, viral spread does not only rely on de
novo productive infection of myeloid cells (10–12), but can be
triggered upon activation ofmucosal myeloid cells via the capture
and storage of large amounts of HIV-1 particles that are later
transferred to target cells, as previously reported for monocyte-
derived DCs (13–15). Once mucosal myeloid cells migrate to
secondary lymphoid tissues for induction of antiviral immune
responses, trapped viruses can be efficiently transferred to CD4+
T cells (10, 11), which become productively infected and fuel
systemic viral dispersion. This highly infectious process is known
as trans-infection, and pioneering work already identified that
migratory HLA-DR+ CD3− cervical cells efficiently captured and
transmitted HIV-1 in trans (5). Recent data also demonstrated
that among all myeloid cell subsets, vaginal and cervical DCs
capture and transport transmitted/founder viruses through the
cervicovaginal mucosa and facilitate infection of target cells
(16, 17).
Although trans-infection was initially attributed to the
capacity of C-type lectin receptors such as DC-SIGN to
specifically bind to the viral envelope glycoprotein of HIV-1 (11),
viral capture in the female genital mucosa is independent of this
particular receptor, as the majority of cervical DCs capturing
HIV-1 do not express DC-SIGN (18) and neutralizing antibodies
against DC-SIGN cannot block viral transmission (5). In addition
to C-type lectin receptors, HIV-1 capture by myeloid cells is
mediated by the sialic acid binding immunoglobulin-like lectin-
1 (Siglec-1/CD169) (19–21). This receptor potently enhances
HIV-1 capture and storage in virus containing-compartments
(22), that are later released from DCs to infect target cells via
virological synapse formation (23). Siglec-1 is present on the
surface of myeloid cells and its expression is potently enhanced
by type-I interferon signaling (21, 24), which is triggered by
viral immune sensing or bacterial lipopolysaccharide exposure,
both factors associated to HIV-1 infection (25). However, it does
not bind to the envelope glycoprotein of HIV-1 as C-type lectin
receptors do (11), but recognizes sialylated gangliosides that
are anchored on the viral membrane of enveloped retroviruses
(19, 26). In vivo, Siglec-1 is required for robust infection and
early dissemination of a retrovirus within the lymphoid tissue of a
murine model (27), but its potential role during HIV-1 infection
in the female genital tract remains unexplored.
Here we sought to clarify if trans-infection mediated by
Siglec-1 could impact the early stages of HIV infection in
women, and performed a comprehensive analysis of Siglec-
1 expression on human cervical anatomical compartments.
In all samples studied, we identified mucosal DCs expressing
this receptor, whose expression was boosted by interferon alfa
(IFNα) antiviral signaling. Moreover, we also found that cervical
DCs enhanced viral capture and trans-infection, and that this
mechanism was effectively prevented with antibodies against
Siglec-1 receptor.
RESULTS
Myeloid Cells From Human Cervical
Submucosa Express Siglec-1
We first analyzed Siglec-1 expression by flow cytometry on
human cervical mononuclear cells obtained from tissues from
benign hysterectomies processed immediately after prescribed
surgery. Gating on hematopoietic CD45+, single and viable cells
allowed identifying myeloid CD3− HLA-DR+ cells (Figure 1A),
which represented a mean of 6 and 7.5 % of cells at the
ectocervix and endocervix, respectively (red gate and bar graph,
Figure 1B). Of note, HLA-DR− cells did not express Siglec-
1 (gray and brown gates, Figure 1C). However, among the
myeloid HLA-DR+ fraction, a mean of 24.5 and 11.5 % of cells
expressed Siglec-1 in the ectocervix and endocervix, respectively
(blue gate and bar graph, Figure 1D). Moreover, these cells
were predominantly CD11c+ CD14+ (pink gate and bar graph,
Figure 1E) and CD11b+ (orange gate, Figure 1F). In contrast,
myeloid HLA-DR+ cells lacking Siglec-1 expression represented
three distinct subsets: CD11c− CD14+, CD11c+ CD14− and
CD11c+ CD14+ cells (Figure 1G). Of note, Siglec-1+ cells
displayed a higher activation status than Siglec-1− cells as seen
by HLA-DR expression levels (Supplemental Figure 1). These
results identify Siglec-1+ myeloid cells at the ectocervix and
endocervix as a subset that displays typical markers of interstitial
cervical DCs, such as HLA-DR, CD11c, CD14, and CD11b (28).
Siglec-1+ Cells Accumulate in the
Submucosa of the Ectocervix
and Endocervix
To analyze the localization of Siglec-1+ cells within the cervix,
we next performed immunofluorescence of mucosal tissues
from women undergoing benign hysterectomies. Siglec-1+ cells
predominantly located in the lamina propria or submucosa
and, in agreement with flow cytometry data, were also positive
for CD14 or CD11c (Figure 2A). In contrast, no Siglec-1+
cells were found in the lower region of the epithelium, where
CD207/langerin+ Langerhans cells are commonly found (29).
Immunohistochemistry staining of cervicovaginal tissues further
identified Siglec-1+ cells displaying myeloid cell morphology
mostly accumulated within the submucosa of the ectocervix,
which is lined by a stratified squamous epithelium (Figure 2B,
left). Siglec-1+ cells were also found in the endocervix,
which is covered only by a single-layer columnar epithelium
(Figure 2B, right), although the frequency was lower than at
the ectocervix. However, in those endocervical tissues classified
as highly inflamed based on histopathological detection of
inflammatory infiltrates, we found a higher number of Siglec-
1+ cells (Figure 2C) that were comparable to those observed at
the ectocervix (Figure 2B, left graph). Of note, the reasons for a
higher inflammatory infiltrate could not be attributed to the HIV-
1 infection status, the level of viral load, age or any particular
clinical indication for surgery (Table 1). These results identified
the presence of myeloid cells expressing Siglec-1 in the steady
state just beneath the mucosa of the ectocervix and endocervix,
where cervical DCs usually accumulate (16).
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FIGURE 1 | Myeloid cells from human cervical mucosa express Siglec-1. FACS analysis and representative gating strategy of the cervicovaginal myeloid cell subsets.
Colored gates and arrows indicate populations analyzed, and corresponding matching colors are used to identify bar graphs showing frequencies of those
(Continued)
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FIGURE 1 | populations. (A) Hematopoietic cells were identified by their CD45 expression, and single-live cells were selected by doublet discrimination and live/dead
staining. (B) Representative dot plot and frequency of HLA-DR+ and CD3− on hematopoietic cells. (C) Representative dot plot showing that HLA-DR− cells do not
express Siglec-1. (D) Representative dot plot and frequency of Siglec-1 expression analyzed in HLA-DR+ myeloid cells compared to matched isotype control.
(E) Representative dot plot and frequency of CD11c+ CD14+ cells among myeloid HLA-DR+ cells expressing Siglec-1. (F) Representative dot plot of CD11b
expression analyzed in CD11c+CD14+ Siglec-1+ myeloid cells. (G) Representative dot plot of CD14 and CD11c among the myeloid HLA-DR+ cells that do not
express Siglec-1. All bar graphs show mean values and SEM from 14 donors. Statistical differences were assessed with a Mann-Whitney test.
FIGURE 2 | Siglec-1+ cells accumulate in the submucosa of the ectocervix and endocervix. (A) Representative immunofluorescent stainings on four ectocervix and
endocervix of CD14 (AF488) and Siglec-1 (AF647), or CD11c (AF488) and Siglec-1 (AF647). Scale bars 20µm. (B) Representative images of Siglec-1 immunostaining
(40x) on 10 ectocervix and endocervix. Scale bars 100µm. Insets show Siglec-1+ cells magnification (100x). Bar graph shows the mean values and SEM of
Siglec-1+ cells per field counted in 5 consecutive fields. (C) Representative images of Siglec-1 immunostaining (40x) on 10 endocervix displaying a low and high
grade of inflammation. Scale bars 100µm. Bar graph shows the mean values and SEM of Siglec-1+ cells per field counted in 5 consecutive fields of 10 endocervix
with different inflammation grades. Statistical differences were assessed with a Mann-Whitney test.
DCs From Cervical Mucosa Mediate Viral
Uptake via Siglec-1 and Are Detected
in vivo
To investigate whether Siglec-1+ cervical myeloid cells
could capture and store HIV-1 via the interaction with this
particular I-type lectin receptor, we next pulsed cervical cell
suspensions processed immediately after prescribed surgery
with fluorescent viruses. Cells were incubated with HIV-1
Virus-Like Particles (HIV-1Gag−eGFP VLPs), which lack the
viral envelope glycoprotein but carry sialyllactose-containing
gangliosides recognized by Siglec-1 receptor and recapitulate
HIV-1 uptake results obtained with wild type viruses in myeloid
cells (30, 31). After VLP exposure, cervical mononuclear cells
were extensively washed and assessed by flow cytometry. Among
the single-live CD45+ myeloid HLA-DR+ fraction, a mean of
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TABLE 1 | Clinical data associated to cervical tissues where Siglec-1 was quantified by IHQ.
Patient Siglec-1+ cells per field
at the Ectocervix
Siglec-1+ cells per field
at the Endocervix
Age (yr) Indication for surgery HIV status Viral Load (copies/ml)
1 9,6 2,6 52 Prolapse - NA
2 2,3 3,4 53 Prolapse - NA
3 4,2 7,2* 45 Prolapse - NA
4 13,8 9,2* 52 Prolapse - NA
5 3,6 5,8* 60 Prolapse - NA
6 8,8 4,8 59 Unknown + <50 (ART)
7 6,4 2,4 45 Prolapse + <50 (ART)
8 11,6 3,2 57 Cystocele + 140 (ART)
9 5,4 3 41 Uterine fibroids + 400 Controller (naïve)
10 8 3,2 52 Prolapse + Cystocele + 1.164 (naïve)
Higher levels of inflammation were observed in these tissues*
11.8 and 3.6 % of cells expressed Siglec-1 in the ectocervix and
endocervix (blue gate and bar graph, Figure 3A), while a 14.1
and 7 % of cells captured HIV-1Gag−eGFP VLPs (green gate
and bar graph, Figure 3B). Moreover, cells not capturing VLPs
lacked Siglec-1 expression (gray gate, Figure 3C), while cells that
captured viruses were predominantly Siglec-1+ in most of the
tissues (purple gate and bar graph, Figure 3D). Viral uptake by
Siglec-1+ cells was further confirmed by Amnis-imaging FACS
technology, which allowed microscope inspection of acquired
cells and screening of Siglec-1/VLP co-localization. Amnis viral
capture assays revealed that fluorescent HIV-1Gag−eGFP VLP
localized with Siglec-1 within a virus-containing compartment
(Figure 3E), resembling to the sac-like structures previously
described in monocyte-derived DCs and activated tonsillar
myeloid cells (19, 31). As HIV-1Gag−eGFP VLP had no viral
envelope glycoprotein, observed uptake could only rely on
Siglec-1 recognition of sialylated gangliosides anchored on viral
membranes (26, 30). Thus, Siglec-1+ myeloid cells found in the
ectocervix and endocervix capture HIV-1Gag−eGFP VLP in a
virus-containing compartment via Siglec-1 recognition of viral
membrane gangliosides.
To further assess if Siglec-1+ cervical cells are capable
of capturing wild type HIV-1 during the natural course
of infection, we next investigated the cervical biopsy of
a viremic HIV-1+ patient by immunostaining. Confocal
microscopy analysis revealed that distinct Siglec-1+ cells
found in the cervical submucosa harbored viral p24 antigens
(Figure 3F). Three-dimensional z-stack reconstructions
of Siglec-1+ cells from distinct tissue areas showed virus-
containing compartments that were different from the
p24 staining of productively infected cells lacking Siglec-
1 expression (Figure 3G and Movie 1). Thus, Siglec-1+
cervical cells can trap viruses throughout the course of HIV-1
infection in vivo.
pDCs Exposed to HIV-1 Induce Siglec-1
Expression on DCs via IFNα Secretion
Although the basal expression of Siglec-1 on cervical DCs
already allows viral uptake, the level of expression of this type-
I interferon inducible receptor (21) correlates with viral capture
and transmission efficiency of DCs (20). Hence, right after
HIV-1 infection and once the antiviral type-I IFN responses
are triggered, we hypothesized that IFNα could up-regulate
Siglec-1 expression on cervical DCs and enhance their viral
uptake capacity. In the cervical mucosa, resident myeloid cells
quickly induce type-I IFN responses after HIV/SIV infection
(32). Moreover, plasmacytoid dendritic cells (pDCs), the most
potent producers of IFNα, are soon recruited to the site of initial
retroviral infection (33). Thus, we next assessed if IFNα secreted
by HIV-1-exposed pDCs could trigger Siglec-1 expression on
DCs, mimicking early events of HIV-1 pathogenesis once
infection has been established and type-I IFN antiviral immunity
is mounted. Blood derived pDCs were cultured alone, co-
cultured with an uninfected T cell line or with an HIV-1-infected
T cell line that chronically produces R5-tropic BaL viruses in
the presence or absence of anti-CD4 or isotype monoclonal
antibodies (mAb). HIV-1-exposed pDCs released higher IFNα
compared to non-exposed pDCs (Figure 4A), while blockage of
pDC infection with a mAb against CD4 reduced IFNα secretion
compared to an isotype control (Figure 4A). Accordingly, Siglec-
1 expression was increased on monocyte-derived DCs incubated
with supernatants from HIV-1-exposed pDCs as compared to
supernatants from uninfected pDCs (Figure 4B), and further
inhibited by an anti-CD4 mAb (Figure 4B). Thus, HIV-1 sensing
via viral fusion on pDCs induced IFNα secretion that triggered
Siglec-1 expression on monocyte-derived DCs as potently as
recombinant IFNα (Figure 4C), and was specifically inhibited
by the type-I interferon blocking receptor B18R (Figure 4C).
Moreover, HIV-1-exposed pDCs derived from pre-menopause
women released significantly higher amount of IFNα than
pDCs derived from men (Figure 4D). We also induced Siglec-
1 expression with equal amounts of recombinant IFNα on
monocyte-derived DCs from men and women and determined
the absolute number of Siglec-1 antibody binding sites per
cell (Figure 4E). Under these experimental conditions, however,
DCs derived from women did not significantly express higher
amounts of Siglec-1 than DCs derived from men (Figure 4E).
All together, these results highlight how upon HIV-1 infection,
pDC accumulation in the female genital tract could lead to an
increased antiviral IFNα secretion that could limit viral infection
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FIGURE 3 | DCs from cervical mucosa mediate viral uptake via Siglec-1 and are detected in vivo. (A) Cervical mononuclear cells isolated from the ectocervix and
endocervix of benign hysterectomies were pulsed with VLPs for 18 h at 37◦C, extensively washed, labeled with the indicated mAbs and assessed by FACS. Colored
(Continued)
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FIGURE 3 | gates and arrows indicate populations analyzed, and corresponding matching colors are used to identify bar graphs showing frequencies of those
populations. Representative dot plot and frequency of HLA-DR+ and Siglec-1+ cells on hematopoietic cervical cells. (B) Representative dot plot and frequency of
cells capturing HIV-1Gag−eGFP VLPs among the myeloid HLA-DR
+ fraction. Smaller dot plot in between depicts the control without VLPs. (C) Representative dot plot
showing reduced expression of Siglec-1 in the myeloid HLA-DR+ cells not capturing HIV-1Gag−eGFP VLPs. (D) Representative dot plot of Siglec-1
+ cells among the
cells capturing HIV-1Gag−eGFP VLPs. Bar graphs show mean values and SEM from the ectocervix and endocervix of 4 to 5 donors. (E) Images of Siglec-1
+ cervical
cells pulsed and labeled as in (A). Cells were acquired by Amnis-imaging FACS, and showed green fluorescent HIV-1Gag−eGFP VLPs accumulation within a sac-like
virus-containing compartment enriched in Siglec-1 (labeled in red). (F) Paraffin-embedded cervical tissue from one viremic HIV-infected woman stained for HIV-1 p24
antigen (labeled in red), Siglec-1 (in green), and nucleus (in blue). Scale bar 50µm. (Inset panels) zoom in of squared region with distinct fluorescences (scale bar
20µm). (G) 3D volumetric x-y-z data fields reconstruction of Siglec-1+ cells from four distinct areas of the cervical tissue of the viremic HIV-infected woman. Opacity
representation of DAPI stained nuclei and fluorescence of the sac-like virus-containing compartment (VCC; white arrows). Right bottom image displays a characteristic
cell pattern with p24+ dots reflecting viral production (Infection).
FIGURE 4 | pDCs exposed to HIV-1 induce Siglec-1 expression on DCs via IFNα secretion. (A) IFNα release measured by ELISA on supernatants from blood derived
pDCs co-cultured 24 h alone, with an uninfected MOLT CD4+ T cell line or an HIV-1 infected MOLT CD4+ T cell line that chronically produces R5-tropic BaL viruses in
the presence or absence of 10µg/ml of an anti-CD4 or an isotype mAb. Bar graph shows mean values and SEM from at least 6 donors and 3 independent
experiments. Statistical differences were assessed with a Wilcoxon matched-pairs signed rank test. (B) Induction of Siglec-1 on monocyte-derived DCs incubated
with supernatants isolated from pDCs co-cultured as in (A) and assessed by FACS. (C) Representative histograms of Siglec-1 expression on monocyte-derived DCs
exposed to medium, recombinant IFNα, supernatants from uninfected pDCs, supernatants from HIV-1-exposed pDCs on mock treated DCs or on DCs previously
incubated with the type-I interferon blocking receptor B18R. (D) IFNα release measured by ELISA on supernatants of pDCs isolated from women or men and
co-cultured 24 h with an HIV-1 infected MOLT CD4+ T cell line. Bar graph shows mean values and SEM from 19 donors and 4 independent experiments. Statistical
differences were assessed with a Mann-Whitney test. (E) Quantification of Siglec-1 expression levels on monocyte-derived DCs from men and women assessed by
FACS. Bar graph shows mean values and SEM from 12 donors and 3 independent experiments. Prentice Rank Sum Test was used to assess statistical differences,
which did not reach statistical significance (P = 0.073).
initially, but also promote viral capture of cervical myeloid cells
via Siglec-1 induction.
IFNα Enhances Viral Capture and
Trans-infection on Siglec-1+ Cervical DCs
We next investigated if IFNα could trigger Siglec-1 expression on
cervical myeloid cells and enhance their Siglec-1-mediated viral
capture capacity. Small pieces of ectocervix or endocervix were
cultured overnight (34), in the presence or absence of increasing
concentrations of IFNα and analyzed by flow cytometry after
enzymatic digestion. IFNα induced a dose-response increase
in the percentage of Siglec-1+ cells among the myeloid HLA-
DR+ CD14+ CD11c+ DC fraction (Figure 5A). Moreover, on
cellular suspensions obtained from cervical tissues immediately
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processed after surgery, IFNα treatment also increased the
percentage of Siglec-1+ cells (Figure 5B). This effect was more
prominent in the endocervix, where basal expression of Siglec-
1 was lower (Figures 1D, 5B). Accordingly, IFNα treatment
increased the percentage of cells capturing HIV-1Gag−eGFP VLP
among the myeloid HLA-DR+ CD14+ CD11c+ DC population,
especially at the endocervix (Figure 5C). Thus, endocervical
myeloid cells could mediate trans-infection more potently
once antiviral type I IFN responses are mounted and Siglec-1
expression is triggered on DCs.
Our results suggested that α-Siglec-1 mAbs could offer
protection against HIV-1 uptake and prevent dissemination
mediated by cervical DCs. We therefore pre-incubated cells from
the ectocervix and endocervix with an α-Siglec-1 mAb or isotype
control before viral exposure (Figure 5D). While isotype control
had no inhibitory effect, pre-treatment with α-Siglec-1 mAbs led
to a reduction of HIV-1Gag−eGFP VLP uptake even after IFNα
treatment (Figure 5D). Moreover, this blocking effect was further
confirmed using a wild type R5-tropic HIV-1NFN−SX to pulse
mock treated or IFNα-treated CD3−HLA-DR+ cervical DCs,
which were sorted and co-cultured with a reporter CD4+ cell
line to measure viral transfer via trans-infection (Figure 5E). Of
note, at the steady state, the expression of Siglec-1 on these cells
is shown on Figure 1D. In seven independent cervicovaginal
tissues, we consistently observed a significant decrease in the
levels of HIV-1 transmitted in the α-Siglec-1 mAb treated cells
compared to the isotype control, which accounted for blocking
a mean of 70% of the transferred infectivity by myeloid cells.
Thus, at the basal state but also upon Siglec-1 induction by IFNα,
the α-Siglec-1 mAb could most likely block viral binding and
uptake, preventing subsequent viral transmission from myeloid
cells to target cells. These results highlight that specific inhibitors
against Siglec-1 can halt viral transfer and dispersionmediated by
Siglec-1+ cervical DCs.
DISCUSSION
A preventative strategy aimed at protecting against HIV
infection must block several steps during the earliest stages
of infection, avoiding not only the productive infection of
primary target cells, but also the viral dissemination toward
distal tissues. In both scenarios, antigen-presenting cells residing
in different compartments of the female genital mucosa may
play a prominent role (7, 9, 24, 35). DC-T cell conjugates
represent an optimal milieu for productive HIV infection, which
may boost initial viral replication of CD4+ T cells (10, 36).
Moreover, uninfected DCs could promote HIV dissemination
to draining lymph nodes after mucosal challenge (8, 9). Yet,
the precise molecular mechanism mediating these processes
remained unexplored in the cervicovaginal tissue.
Here we have shown the ability of Siglec-1 to mediate viral
capture and transmission to target cells on a population of
cervical myeloid cells expressing HLA-DR, CD11c, CD14, and
CD11b, all classical markers known to be present on DCs of
the submucosa at the lower female genital tract (18, 28, 29, 37).
Our findings concur with prior studies where the migratory
CD3− HLA-DR+ fraction or the cervicovaginal CD11c+ DCs
were found to be the myeloid cell subset that preferentially
captured and transported HIV-1 out of the cervicovaginal
mucosa (5, 16, 17). Nevertheless, we now show that on DCs of
the ectocervix and endocervix, alternative receptors beyond DC-
SIGN operate in HIV-1 viral uptake and transfer, as previously
reported for monocyte-derived DCs (13, 15, 38–43). Our results
provide a plausible mechanism for previous reports where the
predominant cervical myeloid cell population that capturedHIV-
1 was found to be DC-SIGN negative (18), or where there was
a lack of inhibition of neutralizing antibodies against DC-SIGN
on viral transmission mediated by cervical myeloid cells (5). The
discovery of Siglec-1 expression on myeloid cervical DCs and
the capacity of Siglec-1+ cells to capture viruses in vivo help to
understand how this particular receptor can facilitate boosting of
HIV-1 replication and dissemination from the genital mucosa to
the corresponding draining lymph nodes in the absence of DC
productive infection.
Baseline levels of Siglec-1 on myeloid cells in the lamina
propria of all cervical tissues examined herein already allowed
viral uptake, demonstrating that Siglec-1 could act as a viral
attachment factor even in the absence of prior viral infection.
However, as tissues with a high level of inflammatory infiltrate
showed an increased number in Siglec-1+ cells, ongoing
inflammatory events triggered upon infection could magnify
Siglec-1 mediated HIV-1 uptake and trans-infection. Indeed, in a
cervical biopsy of an HIV-1 viremic woman, we found Siglec-1+
cells with HIV-1-containing compartments, demonstrating that
these cells actually trap viruses and form these compartments
in vivo.
In the female genital tract, type I IFN responses from tissue
resident cells represent a potent first-line of defense against many
pathogens, including lentiviruses (44–47). Soon after infection,
recruited pDCs sensing incoming viruses will strongly contribute
to IFNα secretion (33). Here we confirmed that HIV-1 fusion on
pDCs induced IFNα secretion (48, 49) and that this mechanism,
which is subjected to hormonal regulation (50), was enhanced
in pDCs derived from pre-menopausic women. However, gender
did not affect the IFNα response that triggered Siglec-1 induction
on DCs, as it had been previously reported for other interferon-
stimulated genes during chronic HIV-1 infection (51). Further,
we demonstrated that CD14+ CD11c+ DCs up-regulate Siglec-
1 expression in a dose response manner after IFNα stimulation
of the cervical tissue, especially at the endocervix. In contrast,
higher basal expression of Siglec-1 was found on ectocervical
myeloid cells at the steady state. These data suggest that
while pre-existing basal immune activation at the ectocervix
could already favor Siglec-1 capture of early invading viruses,
endocervical cells will most likely mediate viral uptake at later
time points, once antiviral type I IFN responses are mounted and
Siglec-1 expression is boosted on DCs. Indeed, this could explain
why we only observed an increased number of Siglec-1+ cells
on biopsies from the endocervix that had a high inflammatory
score. Overall, detection of Siglec-1 on cervical DCs contributes
to understand why the IFN system is not more effective against
HIV-1 despite its substantial up-regulation early upon infection
(4, 33, 52). Similarly, it may also explain why treatments inducing
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FIGURE 5 | IFNα enhances viral capture and trans-infection on Siglec-1+ cervical DCs. (A) Percentage of Siglec-1+ DCs within the myeloid HLA-DR+ CD14+
CD11c+ fraction from small pieces of ectocervix or endocervix cultured in the presence or absence of increasing concentrations of IFNα (1,000; 10,000; and 100,000
IU/ml) and assessed by FACS as in Figure 3. Bar graph shows mean values and SEM from 5 donors and 4 independent experiments. Colors depict each particular
donor. Statistical differences were assessed with a one-way repeated measures ANOVA test. (B) Percentage of Siglec-1+ DCs within the myeloid HLA-DR+ CD14+
CD11c+ fraction from cellular suspensions obtained from tissue digestion and cultured in the presence or absence of IFNα. Statistical differences were assessed with
a paired t-test. (C) Percentage of cells capturing HIV-1Gag−eGFP VLPs among the myeloid HLA-DR
+ CD14+ CD11c+ fraction from cellular suspensions obtained
from ectocervix or endocervix digestion and cultured in the presence or absence of IFNα. Statistical differences were assessed with a paired t-test. (D) Percentage of
cells capturing HIV-1Gag−eGFP VLPs as in (C) on cells that had been previously pre-incubated with 20µg/ml of 7D2 anti-Siglec-1 mAb or isotype control. Bar graph
shows mean values and SEM from 2-3 donors. Dot plots showing representative inhibition are also depicted. (E) Relative R5 tropic HIV-1NFN−SX transmission to
CD4+ target cells from cervical CD45+CD3−CD19− HLA-DR+ sorted cells pre-incubated with 20µg/ml of isotype or anti-Siglec-1 mAbs before viral exposure.
Values are normalized to isotype-treated cells (set at 100%). Statistical differences were assessed with a one sample t-test. Mean values and SEM from two
experiments include cells from 3 or 4 donors.
pDC recruitment (53) and a strong type I IFN response (54)
before vaginal challenge in macaques are incapable of limiting
viral infection beyond the infected mucosa and can even enhance
viral replication.
As other sexually transmitted infections such as herpes virus
or chlamydia infection trigger type I IFN responses in mucosal
tissues via pDC recruitment and/or bacterial lipopolysaccharide
exposure (55, 56), it would be important to explore the role
of Siglec-1 in favoring HIV-1 acquisition, replication and
dissemination in women with pre-existing sexually transmitted
infections (2). Moreover, since inflammatory CD14+ CD11c+
DCs are known to induce Th17 T-cell differentiation (57), and
these are the preferential targets of viral infection in the cervix
right after retroviral invasion (58), it would also be critical to
evaluate the role of this Siglec-1+ DC subset on susceptibility to
HIV-1 infection.
In summary, myeloid DCs expressing a key molecule involved
in HIV-1 trans-infection, namely Siglec-1, are found in the
cervical tissues of women in the basal state. IFNα-treated
myeloid DCs up-regulate Siglec-1 expression, which increases
viral capture and trans-infection, providing an explanation of
how the virusmay succeed in an otherwise antiviral environment.
We propose that Siglec-1+ cervical DCs may facilitate HIV-1
transfer to bystander CD4+ T cells and favor the nascent
infection within the cervical mucosa, but also facilitate early
dissemination to secondary lymphoid tissues. These findings
highlight the importance of including Siglec-1 inhibitors along
with potent antiretroviral agents in forthcoming microbicidal
strategies, to stop not only the productive cellular infection in the
cervix, but also the systemic viral dissemination from the female
genital tract.
METHODS
Cervical Tissue Digestion
and Immunophenotype
Human cervical tissue was obtained from women (age range
39–82 years) undergoing hysterectomy for non-neoplasic
indication at either HUGTiP or Hospital Municipal de Badalona.
After confirmation of healthy tissue status by the Pathology
Service, a piece from ectocervix and endocervix separated
by anatomical localization was delivered to the laboratory
in tissue media [RPMI 1640 supplemented with 15 % FBS,
500 U/mL penicillin, 500µg/mL streptomycin, 2.5µg/mL
Fungizone (Life Technologies), 50µg/mL gentamicin, MEM-
non essential aminoacids (Gibco) and 1mM MEM-sodium
pyruvate (Gibco)]. Tissue was processed within the next 24 h
after surgery. The mucosal epithelium and the underlying
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stroma of both ectocervix and endocervix were separated from
muscular tissue and dissected into approximately 8-mm3 blocks.
Depending on the experiment, tissue blocks were cultured,
digested or included in optimal cutting temperature compound
for immunofluorescence as previously described (34).
For tissue digestion, five to eight pieces from ectocervix or
endocervix were separately placed into 1.5 ml-tubes containing 5
mg/ml collagenase IV (Invitrogen) in RPMI 1640 supplemented
with 5% fetal bovine serum (FBS, Gibco). Tubes were shaked at
400 rpm at 37◦C for 30min. After enzymatic digestion, tissue
blocks were dissociated manually with a disposable pellet pestle
in two series of 20 rotations while pulling it up and down. The
suspension was filtered through a 70µm cell strainer (SPL Life
Sciences), and cells were collected at 16◦C after washing with
PBS. Cells were then stained with Live/Dead Aqua (Invitrogen)
for 30min at RT. Pellet was suspended in staining buffer
(1% mouse serum, 1% goat serum in PBS) and stained with
CD14-V450 (MØP9), CD11c-PE-Cy7 (B-ly6), HLA-DR-PerCP-
Cy5.5 (G46-6), (all from BD Biosciences), CD3-eVolve 655
(OKT3) (eBiosciences), CD45-Alexa Fluor 700 (Hl30), CD11b-
FiTC (M1/70), Siglec-1-PE (7-239) (all from BioLegend). Mouse
IgG1-PE (BioLegend) was used as isotype control. Cells were
acquired using a BD LSRFortessa SORP flow cytometer (Flow
Cytometry Platform, IGTP) and analyzed with FlowJo vX.0.7
software (TreeStar).
Immunofluorescence
Cervical 5-µm cryosections were dried at RT, fixed in 3.7%
formaldehyde (Sigma Aldrich) diluted in PHEM buffer as
previously described in (34), permeated with 0.2% Triton X-
100 (Sigma Aldrich) in PHEM buffer and blocked with 0.2%
cold fish gelatin (Sigma Aldrich), 0.1% Triton X-100 and 10%
normal goat serum (Gibco) diluted in PBS. Sections were first
incubated with the following primary mAbs: mouse anti-Siglec-
1 7-239 Ab (Abcam), rabbit anti-CD11c EP1347Y Ab (Abcam)
or rabbit anti-CD14 EPR3653 Ab (Abcam). Samples were then
washed extensively with PBS and incubated with the secondary
mAbs Alexa 488-conjugated donkey anti-rabbit or Alexa 647-
conjugated donkey anti-mouse IgG (Jackson ImmunoResearch).
Sections were covered with mounting medium (ProLong
TM
Gold
Antifade Mountant with DAPI, Life Technologies, Invitrogen)
and a coverslip. Images were obtained by confocal microscopy
using a Zeiss LSM 710 microscope and the Zen Blue Image
acquisition software.
Immunohistochemistry
Ten cervical formalin-fixed, paraffin-embedded samples from the
Pathology Department of HUGTiP were analyzed. Of note, we
chose samples from five HIV-1 infected and five seronegative
women, but results were equivalent regardless of the HIV status.
Immunohistochemical stains were performed using a Ventana
Benchmark Ultra (Ventana Medical Systems) in accordance with
the manufacturer’s protocol, with standard antigen retrieval (pH
9.0; Ventana) and the mAb against α-Siglec-1 (clone SP213, LS
Biosciences, dilution 1/100) for 12min. A pathologist carried
out a blind quantification of Siglec-1+ cells and images were
captured using a DP71 digital camera (Olympus, Center Valley,
PA, USA) attached to a BX41 microscope (Olympus). Siglec-
1+ cells in five consecutive fields in the subepithelial area
were counted for ectocervix and endocervix separately. Tissues
where a significant inflammatory infiltrate was detected were
considered as highly inflamed.
Cell Lines
HEK-293T cells obtained from ATCC (CRL-11268) and TZM-
bl (obtained through the US National Institutes of Health
[NIH] AIDS Research and Reference Reagent Program) were
maintained in Dulbecco’s Modified EagleMedium (DMEM). The
human T cell lines MOLT CD4+ uninfected and MOLT CD4+
HIV-1BaL infected have been described elsewhere (59) and were
grown in RPMI. All media contained 10% FBS, 100 U/ml of
penicillin and 100µg/ml of streptomycin (all from Invitrogen).
HIV-1Gag-eGFP VLP and HIV-1 Generation
Fluorescent HIV-1 virus-like particles (HIV-1Gag−eGFP VLP)
were generated transfecting HEK-293T cells with plasmid
pGag-eGFP obtained from the NIH AIDS Research and
Reference Reagent Program. Replication-competent HIV-1 stock
was generated by transfecting the proviral construct NFN-
SX, an HIV-1NL43 provirus that expresses the HIV-1JRFL
envelope glycoprotein (kindly provided by W. O’Brien). Thirty
micrograms of plasmid DNA were added to cells in T75 flasks,
and transfection was performed using a calcium phosphate
kit (CalPhos, Clontech). Forty-eight hours post-transfection,
supernatants were harvested, filtered (Millex-HV, 0.45 µm;
Millipore) and frozen at −80◦C until use. The p24Gag content
of the VLP and HIV-1 stock was determined by ELISA
(PerkinElmer). TCID50 or 50% tissue culture infective doses
of HIVNFN−SX-infection used for trans-infection assays were
determined by end-point dilution culture on the cell line TZM-bl,
which contains an HIV long terminal repeat linked to a luciferase
reporter gene.
VLP Uptake Assays
1 × 106 digested ectocervical and endocervical cells were pre-
incubated for 15min at RTwith 20µg/ml of an anti-Siglec-1mAb
(7D2) (Abcam), amurine IgG1 κ isotype control (BDPharmigen)
or left untreated. Cells were pulsed overnight with 2.7- 20 ng
p24Gag HIV-1Gag−eGFP VLP at 37
◦C in a 5%CO2 incubator in the
presence or absence of 1,000 IU/ml of recombinant Interferon-
2α (Sigma-Aldrich) in 10% FBS RPMI with antibiotics. After
extensive washing, cells were stained as previously described and
acquired using a BD LSRFortessa SORP flow cytometer (Flow
Cytometry Platform, IGTP) and analyzed with FlowJo v10.3
software (TreeStar).
For imaging flow cytometer analyses, 1 × 106 digested
ectocervical and endocervical cells were pulsed with HIV-
1Gag−eGFP VLP as previously described. After extensive washing,
cells were resuspended in PBS with 1:250 Live/Dead Aqua
(Invitrogen) and incubated for 30min at RT. Cells were then fixed
and permeabilized (Fix & Perm; Invitrogen), and stained with an
anti-Siglec-1-PE mAb (7-239) (BioLegend). Cells were acquired
with an Amnis ImageStreamX imaging flow cytometer (Merck),
and analyzed using IDEAS v6.1 software. A gradient root mean
Frontiers in Immunology | www.frontiersin.org 10 April 2019 | Volume 10 | Article 825
Perez-Zsolt et al. Cervical Siglec-1+ DCs trans-infect HIV-1
square or RMS value > 40 was established as the best focus
threshold, and single cells were selected in the Area vs. Aspect
Ratio dot plot of the bright field channel.
HIV-1 p24 Immunostaining
A cervical formalin-fixed, paraffin-embedded sample from a
viremic patient diagnosed with sexually transmitted HIV-1
infection a decade ago was obtained from the Pathology
Department of the University Hospital Vall d’Hebron. The
sample was collected when the patient had between 5,160
and 10,400 HIV-1 RNA copies/ml in blood. Samples were
de-waxed and placed in decreasing ethanol concentrations.
Heat-induced epitope retrieval was performed in EDTA buffer
pH 9 (Abcam) in a water bath at 100◦C during 10min.
Slides were permeabilized with Tris-bufferd saline 1X (TBS)
(Fisher scientific) with 0.1% Triton X-100 and 1% BSA (Sigma-
Aldrich) for 10min. Subsequently, blocking was performed
with TBS 1x supplemented with 10% donkey serum (Jackson
Immunoresearch) and 1%BSA for 2h.Mouse anti-p24mAb (Kal-
1; Dako-Agilent) was incubated overnight at 4◦C. Later, rabbit
anti-Siglec-1 mAb (SP213; Lifespan Bioscience) was incubated
for 15min at RT. Samples were then stained with secondary
antibodies Donkey AlexaFluor 647 anti-mouse (Invitrogen)
and Donkey AlexaFluor 488 anti-rabbit; counter stained with
DAPI (Thermo Fisher) and mounted with Fluoromount G
(eBioscience). Samples were imaged on an Olympus Spectral
Confocal Microscope FV1000 using a 20x and 60x phase
objective and sequential mode to separately capture the
fluorescence at an image resolution of 800 × 800 pixels. Image
J software was used for image processing. Alternatively, samples
were acquired in z-stacks every 0.2µm on a Zeiss LSM 780
confocal inverted microscope with an apochromatic 63x oil
(NA = 1.4) and processed with Volocity software using the 3D
Opacity module for reconstruction.
Primary Cell Cultures
Peripheral blood mononuclear cells (PBMCs) were obtained
from buffy coats of the Banc de Sang i Texits of Barcelona
by Ficoll-Hypaque density gradient centrifugation (Alere
Technologies AS). Plasmacytoid DCs were negatively isolated
using magnetic beads from the Plasmacytoid Dendritic Cell
isolation kit (Miltenyi Biotech) and immediately used for
experiments. Monocytes were isolated using CD14+ selection
magnetic beads (Miltenyi Biotech) and differentiated into
monocyte-derived DCs with 1,000 IU/ml of granulocyte-
macrophage colony-stimulating factor plus 1,000 IU/ml of
Interleukin-4 (both from R&D) during 5 days before supernatant
exposure. Cells were maintained in RPMI supplemented with
10% FBS, 100 U/ml of penicillin and 100µg/ml of streptomycin.
IFNα Release on Supernatants From pDCs
and Siglec-1 Induction
A total of 0.1 × 106 pDCs were co-cultured with 0.1 × 106 HIV-
1BaL-infected MOLT-4 cells for 24 h at 37
◦C. Before co-culture,
some pDCs were also pre-treated with 10µg/ml of anti-CD4
mAb (clone RPA T-4) to avoid viral fusion or with an isotype
mAb control (both from Beckton Dickinson) for 10min at RT.
As a negative control, pDCs were co-cultured with an uninfected
MOLT-4 cell line. After 24 h of co-culture, supernatants were
collected and assessed for IFNα production with VeriKine
Human IFN Alpha Elisa Kit (pbl Assay Science). Alternatively,
supernatants from these co-cultures were transferred to 0.2× 106
DCs to assess Siglec-1 induction 24 h later with a FACSCalibur,
labeling cells with a mAb anti-Siglec-1-PE or a matched isotype-
PE control (both from AbD Serotec). Of note, these supernatants
were also added to DCs that had been previously incubated with
2µg/ml of carrier-free recombinant B18R protein (eBioscience)
to block type I IFN receptor. DCs were also cultured in
the presence of RPMI media or 1,000 IU/ml of recombinant
Interferon-2α. The mean number of Siglec-1 Ab binding sites per
monocyte-derivedDC frommen andwomenwas obtained with a
Quantibrite kit (Becton-Dickinson) as previously described (13).
Cervical Tissue Stimulation With IFNα
After dissection of the tissue as previously described, five pieces
from ectocervix or endocervix were separately placed into a 12-
well plate containing 1ml of tissue culture medium. Interferon-
2α was added to the medium at 1,000; 10,000 or 100,000 IU/ml.
After 24 h at 37◦C in 5% CO2, tissue was digested and the
remaining culture plate was treated with accutase (Thermo Fisher
Scientific) for 30min at 37◦C to detach adherent cells. Finally,
tissue and adherent cells were pooled together and stained for
flow cytometry as previously described.
Trans-infection Experiments
Ectocervical and endocervical blocks from HIV-1 non-infected
donors were left untreated or incubated overnight with 10,000
U/ml of IFNα and 100 ng/ml of CCL19 (Mip-3β). Tissue was then
digested, pooled together and stained with mAbs as previously
described to sort single CD45+CD3−CD19−HLA-DR+ live cells
by FACS. Recovered cells were pre-incubated with anti-Siglec-
1 7D2 or isotype control mAbs for 10min at RT. Cells were
subsequently incubated with 185 ng of p24/ml of an R5 tropic
HIV-1NFN−SX (with an estimated TCID50 of 116.824) in the
presence of 20µg/ml of the indicated mAbs for 4 h at 37◦C.
After extensive washes, myeloid cells were co-cultured with the
reporter TZM-bl cell line at a 1:1 ratio for 48 h. Luciferase activity
was measured with Britelite plus (Perkin Elmer) in a Synergy MX
luminometer (Biotek).
Statistical Analysis
Data are reported as the mean and the standard error of the
mean (SEM) for each condition. We analyzed mean changes
using Mann-Whitney test, Wilcoxon matched-pairs signed rank
test, paired t-test, and one-way repeated measures ANOVA test
as indicated, which were considered significant at P < 0.05.
Significant mean changes from 100% of the data normalized to
percentages were assessed with a one sample t-test, considered
significant at P < 0.05. Gender main effect inference across
multiple experiments was assessed using the Prentice Rank Sum
Test, a generalized Friedman rank sum test with replicated
blocked data. All analyses and figures were generated with the
GraphPad Prism v7 Software and R v3.5.
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Movie 1 | 3D volumetric x-y-z data field reconstruction of a Siglec-1+ cell from
the cervical tissue of a viremic HIV-infected woman. Opacity representation of
DAPI stained nuclei and fluorescence of the sac-like virus-containing
compartment along with Siglec-1 staining.
Supplemental Figure 1 | Representative histograms of HLA-DR expression
comparing the Siglec-1 positive and negative populations on CD3− CD11c+
CD14+ cells from the ectocervix and endocervix. Bar graphs show the geometric
mean fluorescence values and SEM of HLA-DR expression from 14 donors.
Statistical differences were assessed with a Wilcoxon matched-pairs signed
rank test.
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